+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Time course proteomic profiling of human myocardial infarction plasma samples: an approach to new biomarker discovery



Time course proteomic profiling of human myocardial infarction plasma samples: an approach to new biomarker discovery



Clinica Chimica Acta; International Journal of Clinical Chemistry 412(11-12): 1086-1093



The aim of this study was to identify novel candidate biomarker proteins differentially expressed in the plasma of patients with early stage acute myocardial infarction (AMI) using SELDI-TOF-MS as a high throughput screening technology. Ten individuals with recent acute ischemic-type chest pain (<12 h duration) and ST-segment elevation AMI (1STEMI) and after a second AMI (2STEMI) were selected. Blood samples were drawn at six times after STEMI diagnosis. The first stage (T0) was in Emergency Unit before receiving any medication, the second was just after primary angioplasty (T2), and the next four stages occurred at 12 h intervals after T0. Individuals (n=7) with similar risk factors for cardiovascular disease and normal ergometric test were selected as a control group (CG). Plasma proteomic profiling analysis was performed using the top-down (i.e. intact proteins) SELDI-TOF-MS, after processing in a Multiple Affinity Removal Spin Cartridge System (Agilent). Compared with the CG, the 1STEMI group exhibited 510 differentially expressed protein peaks in the first 48 h after the AMI (p<0.05). The 2STEMI group, had ~85% fewer differently expressed protein peaks than those without previous history of AMI (76, p<0.05). Among the 16 differentially-regulated protein peaks common to both STEMI cohorts (compared with the CG at T0), 6 peaks were persistently down-regulated at more than one time-stage, and also were inversed correlated with serum protein markers (cTnI, CK and CKMB) during 48 h-period after IAM. Proteomic analysis by SELDI-TOF-MS technology combined with bioinformatics tools demonstrated differential expression during a 48 h time course suggests a potential role of some of these proteins as biomarkers for the very early stages of AMI, as well as for monitoring early cardiac ischemic recovery.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056583237

Download citation: RISBibTeXText

PMID: 21356205

DOI: 10.1016/j.cca.2011.02.030


Related references

Proteomic profiling of human plasma for cancer biomarker discovery. Proteomics 17(6): -, 2016

An application of the 2-nitrobenzenesulfenyl method to proteomic profiling of human colorectal carcinoma: A novel approach for biomarker discovery. Proteomics. Clinical Applications 2(6): 925-935, 2008

Proteomic Biomarker Discovery in 1000 Human Plasma Samples with Mass Spectrometry. Journal of Proteome Research 15(2): 389-399, 2016

Proteomic analysis of plasma samples from patients with acute myocardial infarction identifies haptoglobin as a potential prognostic biomarker. Journal of Proteomics 75(1): 229-236, 2012

Differential gel-based proteomic approach for cancer biomarker discovery using human plasma. Methods in Molecular Biology 854: 223-237, 2012

Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Science 98(2): 201-213, 2007

Proteomic profiling of ovine serum by SELDI-TOF MS: optimisation, reproducibility and feasibility of biomarker discovery using routinely collected samples. Comparative Immunology, Microbiology and Infectious Diseases 33(1): 47-63, 2008

A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX-LC-MS/MS. Molecular and Cellular Biochemistry 343(1-2): 91-99, 2011

Cancer biomarker discovery in plasma using a tissue-targeted proteomic approach. Cancer Epidemiology, Biomarkers & Prevention 16(10): 1915-1917, 2007

Capillary electrophoresis coupled to mass spectrometry for proteomic profiling of human urine and biomarker discovery. Methods in Molecular Biology 564: 105-121, 2009

A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation. Journal of Biomedicine & Biotechnology 2010: 927917-927917, 2010

Utilizing human blood plasma for proteomic biomarker discovery. Journal of Proteome Research 4(4): 1073-1085, 2005

LC-MS profiling of N-Glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma. Journal of Proteome Research 13(11): 4859-4868, 2015

Proteomic global profiling for cancer biomarker discovery. Methods in Molecular Biology 492: 309-320, 2009

Proteomic profiling of pancreatic cancer for biomarker discovery. Molecular & Cellular Proteomics 4(4): 523-533, 2005